Myriad Genetics (MYGN) Cash from Operations (2009 - 2026)

Myriad Genetics has disclosed Cash from Operations across 18 years of filings, most recently posting 15700000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 3.68% year-over-year to 15700000.0; the TTM figure through Mar 2026 stood at 2400000.0 (up 137.5% YoY), while the FY2025 annual figure was 1800000.0, up 120.69% from the prior year.
• Cash from Operations slipped to 15700000.0 in Q1 2026, from 10600000.0 in the prior quarter.
• Over the last five years, Cash from Operations for MYGN reached as high as 21100000.0 in Q3 2025 and fell as low as 54700000.0 in Q4 2023.
• The 5-year median for Cash from Operations is 13600000.0 (2025), against an average of 14105882.35.
• Annual changes were most pronounced in 2022 — Cash from Operations tumbled 1029.55% — and 2025, when it surged 2914.29%.
• A 5-year view of Cash from Operations shows it stood at 7300000.0 in 2022, then sank by 649.32% to 54700000.0 in 2023, then surged by 112.07% to 6600000.0 in 2024, then soared by 60.61% to 10600000.0 in 2025, then sank by 248.11% to 15700000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 15700000.0, 10600000.0, and 21100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.